Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK2 | P25098 | 20/20 | 0.68 |
| ▸ | GRK5 | P34947 | 8/20 | 0.68 |
| ▸ | GRK3 | P35626 | 8/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14496330 | 0.87 | GRK2 (0.68) | GRK2GRK5GRK3 | |
| SCHEMBL14496404 | 0.83 | GRK2 (0.64) | GRK2GRK5GRK3 | |
| SCHEMBL14496282 | 0.80 | GRK2 (1.00) | GRK2GRK5GRK3 | |
| SCHEMBL14496279 | 0.80 | GRK2 (1.00) | GRK2GRK5GRK3 | |
| SCHEMBL14496285 | 0.80 | GRK2 (1.00) | GRK2GRK5GRK3 | |
| SCHEMBL14496290 | 0.80 | GRK2 (1.00) | GRK2GRK5GRK3 | |
| SCHEMBL14496277 | 0.79 | GRK2 (1.00) | GRK2GRK5GRK3 | |
| SCHEMBL14496311 | 0.78 | GRK2 (0.77) | GRK2GRK5GRK3 | |
| SCHEMBL14496324 | 0.78 | GRK2 (1.00) | GRK2GRK5GRK3 | |
| SCHEMBL14496318 | 0.77 | GRK2 (1.00) | GRK2GRK5GRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135499-A1 | Hydrazide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2007-06-14 | — | — | US | disclosed |
| US-20070135499-A1 | Hydrazide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2007-06-14 | — | — | US | disclosed |
| WO-2007008942-A2 | PHENYLAMINO-ACETIC ACID [1-(PYRIDIN-4-YL)-METHYLIDENE]-HYDRAZIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF G PROTEIN-COUPLED RECEPTOR KINASES FOR THE TREATMENT OF EYE DISEASES | AERIE PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007008942-A2 | PHENYLAMINO-ACETIC ACID [1-(PYRIDIN-4-YL)-METHYLIDENE]-HYDRAZIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF G PROTEIN-COUPLED RECEPTOR KINASES FOR THE TREATMENT OF EYE DISEASES | AERIE PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135499-A1 | Hydrazide compounds | GRK4, GRK2, GRK1 | GRK2 2/4885GRK5 5/4885GRK3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.